Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SRRK

DatePrice TargetRatingAnalyst
11/26/2024$40.00 → $50.00Buy
H.C. Wainwright
10/7/2024$30.00 → $35.00Buy
H.C. Wainwright
3/28/2024$30.00Strong Buy
Raymond James
10/25/2023$20.00Hold → Buy
Jefferies
4/3/2023$26.00Overweight
Piper Sandler
9/19/2022$30.00Buy
H.C. Wainwright
7/12/2022$20.00Buy
Truist
3/23/2022$24.00Buy
H.C. Wainwright
More analyst ratings

$SRRK
Press Releases

Fastest customizable press release news feed in the world

See more
  • FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

    Apitegromab remains on track to be the first and only muscle-targeted treatment for people living with Spinal Muscular Atrophy FDA to review BLA application under priority review, with a PDUFA date of September 22, 2025 Apitegromab Marketing Authorisation Application to the European Medicines Agency validated and under review Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

    Primary endpoint showed clinically meaningful improvement in patients with SMA receiving apitegromab as measured by gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo (p=0.0192), with consistent outcomes across all major sub-groups including age, SMN-targeted background therapy, and age at initiation of SMN-targeted therapy Pre-specified secondary endpoint showed that 30.4% of patients receiving apitegromab had ≥ 3-point improvement in HFMSE versus 12.5% of patients on placebo (nominal p-value = 0.0156), despite all study patients receiving ongoing SMN-targeted background therapy In other pre-specified secondary endpoints, patients with SMA receiving apite

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 65,027 shares of common stock and inducement restricted stock units, covering an aggregate of 48,773 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SRRK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SRRK
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SRRK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SRRK
SEC Filings

See more

$SRRK
Leadership Updates

Live Leadership Updates

See more
  • Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SRRK
Financials

Live finance-specific insights

See more
  • FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

    Apitegromab remains on track to be the first and only muscle-targeted treatment for people living with Spinal Muscular Atrophy FDA to review BLA application under priority review, with a PDUFA date of September 22, 2025 Apitegromab Marketing Authorisation Application to the European Medicines Agency validated and under review Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

    Primary endpoint showed clinically meaningful improvement in patients with SMA receiving apitegromab as measured by gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo (p=0.0192), with consistent outcomes across all major sub-groups including age, SMN-targeted background therapy, and age at initiation of SMN-targeted therapy Pre-specified secondary endpoint showed that 30.4% of patients receiving apitegromab had ≥ 3-point improvement in HFMSE versus 12.5% of patients on placebo (nominal p-value = 0.0156), despite all study patients receiving ongoing SMN-targeted background therapy In other pre-specified secondary endpoints, patients with SMA receiving apite

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 65,027 shares of common stock and inducement restricted stock units, covering an aggregate of 48,773 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth

    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SRRK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more